Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Andrew Menzies-Gow1_Michael Wechsler2_2024
VIEWPOINTS

EGPA Remission with Fasenra: Michael Wechsler and Andrew Menzies Gow in Conversation with PharmaShots

Shots:  An already established biologic treatment for SEA in the US, EU5 & Japan. Fasenra is now showing exemplary remission for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)  Today, at PharmaShots, we have a distinguished panel of speakers shedding light on advancements under the P-III MANDARA study and the recent publication of the study…
May 15, 2024

Read more

PharmaShots Interview GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
VIEWPOINTS

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA) Shots: Nucala can now be given by a child’s HCPs or administered…
May 4, 2022

Read more

Viewpoints_Thomas C. Corbridge
VIEWPOINTS

PharmaShots Interview: GSK’s Thomas C. Corbridge Shares Insights on the New Survey Data for Severe Eosinophilic Asthma Patients

In an interview with PharmaShots, Thomas C. Corbridge, US Senior Medical Lead at GSK shares his views on the new survey and demonstrated dissatisfaction with the asthma treatment paradigm Shots: The survey was commissioned by GSK and conducted by The Harris Poll in 100 patients aged ≥18yrs. showed that a majority of SEA patients and physicians are concerned about the current state…
January 18, 2022

Read more